JP2021534206A5 - - Google Patents

Info

Publication number
JP2021534206A5
JP2021534206A5 JP2021509976A JP2021509976A JP2021534206A5 JP 2021534206 A5 JP2021534206 A5 JP 2021534206A5 JP 2021509976 A JP2021509976 A JP 2021509976A JP 2021509976 A JP2021509976 A JP 2021509976A JP 2021534206 A5 JP2021534206 A5 JP 2021534206A5
Authority
JP
Japan
Prior art keywords
gsx1
composition according
protein
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534206A (ja
JP7428404B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046881 external-priority patent/WO2020041142A1/en
Publication of JP2021534206A publication Critical patent/JP2021534206A/ja
Publication of JP2021534206A5 publication Critical patent/JP2021534206A5/ja
Application granted granted Critical
Publication of JP7428404B2 publication Critical patent/JP7428404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509976A 2018-08-23 2019-08-16 Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置 Active JP7428404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721679P 2018-08-23 2018-08-23
US62/721,679 2018-08-23
PCT/US2019/046881 WO2020041142A1 (en) 2018-08-23 2019-08-16 Treating spinal cord injury (sci) and brain injury using gsx1

Publications (3)

Publication Number Publication Date
JP2021534206A JP2021534206A (ja) 2021-12-09
JP2021534206A5 true JP2021534206A5 (enExample) 2022-08-05
JP7428404B2 JP7428404B2 (ja) 2024-02-06

Family

ID=69591287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509976A Active JP7428404B2 (ja) 2018-08-23 2019-08-16 Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置

Country Status (5)

Country Link
US (1) US20210268126A1 (enExample)
EP (1) EP3840729A4 (enExample)
JP (1) JP7428404B2 (enExample)
CA (1) CA3110309A1 (enExample)
WO (1) WO2020041142A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230338529A1 (en) * 2020-08-06 2023-10-26 The Children's Medical Center Corporation Compositions for altering a microglial cell, and methods of use therefore
CN114231489A (zh) * 2020-09-08 2022-03-25 纽伦捷生物医药科技（苏州）有限公司 用于重编程的功能性片段、组合及其应用
CN112812167B (zh) * 2021-01-06 2023-04-11 东北师范大学 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用
CN116879564A (zh) * 2023-09-06 2023-10-13 暨南大学附属第一医院（广州华侨医院） 基于蛋白质组学及磷酸化蛋白质修饰组学的脊髓损伤生物标志物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059939A1 (en) * 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US20120107284A1 (en) * 2006-06-30 2012-05-03 Elena Kozlova Stem cells for transplantation and methods for production thereof
CA2677996C (en) * 2007-02-09 2018-06-12 Eisai R&D Management Co., Ltd. Gaba neuron progenitor cell marker 65b13
WO2010053522A2 (en) * 2008-10-29 2010-05-14 The Regents Of The University Of California Methods for identifying and producing neural stem and progenitor cells and their progeny
WO2010108126A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
US20130189780A1 (en) * 2009-12-31 2013-07-25 Fate Therapeutics, Inc. Reprogramming compositions
RU2556800C2 (ru) * 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
US9487757B2 (en) * 2010-10-26 2016-11-08 Case Western Reserve University Glial cells and oligodendrocytes produced by reprogramming somatic cells with Sox10, Olig2 and Nkx6.2
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
WO2013155222A2 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2018106918A1 (en) * 2016-12-07 2018-06-14 The Children's Medical Center Corporation Neuronal survival and axonal regeneration through increasing mitochondrial motility

Similar Documents

Publication Publication Date Title
JP2021534206A5 (enExample)
Winkler et al. Cholinergic strategies for Alzheimer’s disease
US6776984B1 (en) Induced regeneration and repair of damaged neurons and nerve axon myelin
US9486540B2 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
CN110809476A (zh) 用于神经退行性病症或中风的治疗的基因构建体
JP2021514207A5 (enExample)
JP7428404B2 (ja) Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置
Yadav et al. The development of treatment for Parkinson’s disease
IL324039A (en) Compositions and methods for the treatment of disorders related to cdkl5 deficiency
US20250115650A1 (en) Direct transdifferentiation for treatment of neurological disease
JP7620338B2 (ja) 機能性ニューロンへのグリア細胞の分化転換を誘導するためのＮｅｕｒｏｇ２機能性断片送達システム、宿主細胞及び医薬組成物
Liu et al. Dual-targeting AAV9P1-mediated neuronal reprogramming in a mouse model of traumatic brain injury
JP7680072B2 (ja) リプログラミング用機能性断片、組み合わせ、およびその用途
JP2024534667A5 (enExample)
JP2023540130A5 (enExample)
CN115475247B (zh) β2-微球蛋白或其抑制剂的制药用途
Rodríguez-Campuzano et al. Yin yang 1: function, mechanisms, and glia
JP2023537093A5 (enExample)
Kim et al. Application of Neurotrophic Factors as a Therapeutic Approach for Neurodegenerative Diseases
JP2025508429A5 (enExample)
JP2022525136A5 (enExample)
US20240424140A1 (en) Methods and compositions for direct lineage reprogramming of astrocytes to oligodendrocyte lineage cells
Emborg et al. Viral vector-mediated gene therapy for Parkinson's disease
KR20250057640A (ko) 신경세포 분화 유도용 재조합 벡터 및 이를 포함하는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물
ES2314069T3 (es) Transferencia genica neuronal mejorada.